As the team leader of the Healthcare group, John Stroh’s focus is on Capital Raising, Strategic Partnering and M&A advisory services in the Life Science, Medical Device, Healthcare IT and Healthcare Services sectors
Mr. Stroh has over 30 years of experience in senior management, operations, finance, investment banking and M&A, primarily in the Medical Technology, Life Science and the Healthcare services fields. Prior to 41-North Securities. Mr. Stroh was CEO of Nanospectra, LeuKoDx and Purewick that was sold to Bard in 2017. Prior to this he was President, CEO and Director of NeoMatrix LLC, a breast cancer risk assessment medical device company based in Irvine, California. Prior to NeoMatrix Mr. Stroh was COO & CFO, of Kadmus Pharmaceuticals, A Pharmaceutical Development company that was sold to Schering-Plough at 12 times the original investment.
From 1984 until 2001, Mr. Stroh worked as a Managing Director and Vice President in the investment banking industry for Smith Barney, Shearson-Lehman Brothers, John Nuveen & Company and Piper Jaffray. During this period, he was instrumental in raising over $1 billion for client companies and consulted on over 100 M&A and strategic partnering transactions. He is on the Board of Directors for Orange Coast Memorial Hospital where he is also Chairman of the Finance Committee, and the OCTANe Biomedical Leadership Council.